ALK and lung cancer: Using the example of ALK as a paradigm for ‘rare’ lung cancer clinical research, potential opportunities for further trial development in LCNEC will be the International Rare Cancer Initiative (IRCI) affiliated with the UK National Institute for Health Research (NIHR) and Cancer Research UK, the European Reference Networks (ERNs) created to deal with rare tumours, and the European Organisation for Research and Treatment of Cancer (EORTC) which can be used as a platform for data registration and clinical studies.